News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

David J. Portman

Articles by David J. Portman

TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation

ByDavid J. Portman,Matthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Guiseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Sarah Sammons, MD,Sherry Shen, MD,Christ Twelves,Paul V. Plourde,Senthil Damodaran

April 27th 2025

84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer

ByDavid J. Portman,Timothy Pluard,Jane L. Meisel, MD,Kelly Shanahan,Sarah Sammons, MD,Elizabeth Attias

April 26th 2025

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

37 Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined With Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

ByDavid J. Portman,Senthil Damodaran,Paul V. Plourde,Halle C. F. Moore, MD,Ian C. Anderson

April 27th 2023

Latest Updated Articles

Trending on CancerNetwork

ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care

FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC

How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?

EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma

Pre-Cevostamab Treatment May Not Impact Outcomes as Much in Multiple Myeloma

© 2025 MJH Life Sciences^®

All rights reserved.